Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex

Journal of Clinical Investigation

Volumn 107, Issue 2, 2001, Pages

  Cohn, Ronald D ^a   Durbeej, Madeleine ^a   Moore, Steven A ^a   Coral Vazquez, Ramón ^a   Prouty, Sally ^a   Campbell, Kevin P ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; GLYCOPROTEIN; SARCOGLYCAN; TROPONIN I; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; GENE MUTATION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SMOOTH MUSCLE;

EID: 0035139829     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11642     Document Type: Article

References (27)

1. Prevalence and mortality rate of congestive heart failure in the United States
2. Complexity in simplicity: Monogenic disorders and complex cardiomyopathies
3. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy
4. Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy
5. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy
6. Disruption of the β-sarcoglycan gene reveals a complex pathogenetic mechanism for LGMD 2E
7. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy
8. The molecular basis of muscular dystrophy
9. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene
10. A first missense mutation in the delta sarcoglycan gene associated with a severe phenotype and frequency of limb-girdle muscular dystrophy type 2F (LGMD2F) in Brazilian sarcoglycanopathies
11. Hearr involvement in muscular dystrophy due to sarcoglycan gene mutations
12. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations
13. Cardiomyopathy in Duchenne, Becker and sarcoglycanopathies: A role for coronary dysfunction?
14. Biochemical characterization of the epithelial dystroglycan complex
15. Epsilon-sarcoglycan replaces alpha-sarcoglycan in smooth muscle to form a unique dystrophin-glycoprotein complex
16. Expression of γ-sarcoglycan in smooth muscle and its interaction with the sarcoglycan-sarcospan complex
17. Effects of verapamil on experimental cardiomyopathy in the Bio 14.6 Syrian hamster
18. Prevention of hereditary cardiomyopathy in the Syrian hamster with chronic verapamil therapy
19. Verapamil ameliorates the clinical and pathological course of murine myocarditis
20. Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue
21. Vascular versus myocardial effects of calcium antagonists
22. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy
23. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy
24. Myocardial ischemia in patients with hypertrophic cardiomyopathy: Contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures
25. Comparison of thallium-201 scanning in idiopathic dilated cardiomyopathy and severe coronary artery disease
26. Coronary dilatory capacity in idiopathic dilated cardiomyopathy: Analysis of 16 patients
27. Pathogenesis of chest pain in patients with cardiomyopathies and normal coronary arteries